Cập nhật hướng dẫn S3 về u ác tính buồng trứng 2016
Tóm tắt
Từ khóa
#buồng trứng #khối u ác tính #phân loại TNM #khuyến nghị đồng thuận #mô họcTài liệu tham khảo
Kurman RJ, Carcangiu ML, Herrington CS, Young RHE (2014) WHO Classification of Tumors of Female Reproductive Organs. IARC, Lyon
S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren Kurzversion 2.0 – Oktober 2016. http://www.awmf.org/uploads/tx_szleitlinien/032-035-OLk_Ovarialkarzinom_2016-10.pdf. Zugegriffen: 30.05.2017
S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren Version 2.0 – Oktober 2016 AWMF-Registernummer: 032/035OL. http://www.awmf.org/uploads/tx_szleitlinien/032-035-OLl_Ovarialkarzinom_2016-10.pdf. Zugegriffen: 30.05.2017
Webb JR, Milne K, Watson P, Deleeuw RJ, Nelson BH (2014) Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res 20:434–444
Trainer AH, Meiser B, Watts K, Mitchell G, Tucker K, Friedlander M (2010) Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer. Int J Gynecol Cancer 20:704–716
Tian C, Markman M, Zaino R et al (2009) CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. Cancer 115:1395–1403
Sabatier R, Finetti P, Cervera N, Birnbaum D, Bertucci F (2009) Gene expression profiling and prediction of clinical outcome in ovarian cancer. Crit Rev Oncol Hematol 72:98–109
Harry VN, Gilbert FJ, Parkin DE (2009) Predicting the response of advanced cervical and ovarian tumors to therapy. Obstet Gynecol Surv 64:548–560
Cree IA (2009) Chemosensitivity and chemoresistance testing in ovarian cancer. Curr Opin Obstet Gynecol 21:39–43
Bellati F, Visconti V, Napoletano C et al (2009) Immunology of gynecologic neoplasms: analysis of the prognostic significance of the immune status. Curr Cancer Drug Targets 9:541–565
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2016) S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Kurzversion 2.0, 2016, AWMF-Registrierungsnummer: 032-035OL. http://leitlinienprogramm-onkologie.de/Ovarialkarzinom.61.0.html. Zugegriffen: 23. Mai 2017
Kurman RJ, Shih Ie M (2016) The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol 186:733–747
Malpica A, Deavers MT, Tornos C et al (2007) Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 31:1168–1174
Vang R, Shih Ie M, Kurman RJ (2013) Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology 62:44–58
Mehra K, Mehrad M, Ning G et al (2011) STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci 3:625–634
Visvanathan K, Vang R, Shaw P et al (2011) Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am J Surg Pathol 35:1766–1775
Taylor J, McCluggage WG (2015) Ovarian seromucinous carcinoma: report of a series of a newly categorized and uncommon neoplasm. Am J Surg Pathol 39:983–992
Kobel M, Rahimi K, Rambau PF et al (2016) An Immunohistochemical algorithm for ovarian carcinoma typing. Int J Gynecol Pathol 35(5):430–441
McCluggage WG, Judge MJ, Clarke BA et al (2015) Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol 28(8):1101–1122